A new efficacy test based on hSCARB2 transgenic mice and virulent EV71 strains was developed to overcome the disadvantages of monkey and neonatal mouse models for EV71 vaccine testing.
The development of a new EV71 vaccine efficacy test using hSCARB2 transgenic mice provides a more suitable and reproducible small animal model for vaccine testing.
The development of new vaccines for EV71 relies on the availability of small animal models suitable for in vivo efficacy testing. Monkeys and neonatal mice have been used, but the use of these animals has several drawbacks, including high costs, limited susceptibility, and poor experimental reproducibility. In addition, the related ethical issues are considerable. The new efficacy test based on hSCARB2 Tg mice and virulent EV71 strains propagated in genetically modified cell lines presented here can overcome these disadvantages and is expected to accelerate the development of new EV71 vaccines.
Imura et al. (2020) studied Enterovirus 71 (EV71) infection. hSCARB2 Tg mice and virulent EV71 strains was evaluated. A new efficacy test based on hSCARB2 transgenic mice and virulent EV71 strains was developed to overcome the disadvantages of monkey and neonatal mouse models for EV71 vaccine testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: